Prospective observational study of systemic therapy for unresectable HCC in Japan: Real World data of systemic therapy for HCC
Not Applicable
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000040488
- Lead Sponsor
- Investigator Initiated Study Promotion Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients with a past history of systemic therapy (including molecular targeted therapies, immune checkpoint inhibitors, investigational drugs). Patients with prior history of hepatectomy, local ablative therapy, TACE, and radiation therapy are not excluded. 2 Patients participating in clinical trials requiring some intervention, such as new agents. 3 Patients who are judged to be unsuitable to enroll in the study by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival of each treatment regimen at each treatment line
- Secondary Outcome Measures
Name Time Method Progression free survival, overall response rate, disease control rate and time to treatment failure of each regimen at each treatment line Grade 3 or greater adverse events of each regimen at each treatment line Drug exposure (initial dose, duration of treatment and dose intensity, transition rate to next treatment) of each regimen at each treatment line